Resource Summary Report

Generated by RRID on Sep 8, 2026

LS174T

RRID:CVCL_1384
Type: Cell Line

Proper Citation

RRID:CVCL_1384

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1384

Proper Citation: RRID:CVCL_1384

Description: Cell line LS174T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:1262041, PMID:1999484, PMID:3335022, PMID:3349466, PMID:3518877, PMID:3664476, PMID:6401685, PMID:6652615, PMID:6935474, PMID:7370982, PMID:7459858, PMID:7972006, PMID:8422623, PMID:8464898, PMID:8895552, PMID:9000147, PMID:9290701, PMID:9294210, PMID:10674020, PMID:10737795, PMID:11226274, PMID:11414198, PMID:11416159, PMID:11526487, PMID:12068308, PMID:12606785, PMID:15900046, PMID:16418264, PMID:16854228, PMID:18258742, PMID:19132987, PMID:20164919, PMID:20215515, PMID:20570890, PMID:20606684, PMID:23272949, PMID:24042735, PMID:24755471, PMID:24840470, PMID:25485619, PMID:25877200, PMID:25926053, PMID:25944804, PMID:26537799, PMID:26589293, PMID:28196595, PMID:28683746, PMID:29101300

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS174T

Synonyms: Ls174T, LS174t, Ls-174-T, LS-174-T, LS 174 T, LS-174T, Ls-174T, LS 174T, LS-174, LS174, Laboratory of Surgery 174T

Cross References: BTO:BTO_0001553, CLO:CLO_0007393, CLO:CLO_0007403, EFO:EFO_0002227, MCCL:MCC:0000504, CLDB:cl3261, AddexBio:C0009013/379, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ATCC:CCL-188, ATCC:CL-188, BCRC:60053, BioSample:SAMN03470826, BioSample:SAMN03471296, cancercelllines:CVCL_1384, CCRID:1101HUM-PUMC000248, CCRID:3101HUMTCHu32, CCRID:4201HUM-CCTCC00135, CCTCC:GDC0135, Cell_Model_Passport:SIDM01200, ChEMBL-Cells:CHEMBL3307536, ChEMBL-Targets:CHEMBL614097, CLS:300392, ColonAtlas:LS174T, Cosmic:711255, Cosmic:719679, Cosmic:724843, Cosmic:738927, Cosmic:873703, Cosmic:875424, Cosmic:876717, Cosmic:887219, Cosmic:889533, Cosmic:907793, Cosmic:934563, Cosmic:948131, Cosmic:948856, Cosmic:985998, Cosmic:995405, Cosmic:1043822, Cosmic:1057755, Cosmic:1066210, Cosmic:1122328, Cosmic:1132565, Cosmic:1132692, Cosmic:1184087, Cosmic:1184334, Cosmic:1187310, Cosmic:1312305, Cosmic:1479573, Cosmic:1486134, Cosmic:1524341, Cosmic:1676738, Cosmic:1708419, Cosmic:1805263, Cosmic:2301546, Cosmic:2301997, Cosmic:2646768, Cosmic:2651866, Cosmic:2668256, Cosmic:2760087, Cosmic:2787546, DSMZ:ACC-759, DSMZCellDive:ACC-759, ECACC:87060401, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM513911, GEO:GSM514297, GEO:GSM741264, GEO:GSM784021, GEO:GSM827345, GEO:GSM1346883, GEO:GSM1374632, GEO:GSM1374633, GEO:GSM1448164, GEO:GSM2550009, IARC_TP53:21478, IARC_TP53:21708, IGRhCellID:LS174T, KCB:KCB 200829YJ, KCLB:10188, LINCS_LDP:LCL-1182, Lonza:1127, MetaboLights:MTBLS227, NCBI_Iran:C568, PharmacoDB:LS174T_862_2019, PRIDE:PXD005354, PRIDE:PXD005355, Progenetix:CVCL_1384, PubChem_Cell_line:CVCL_1384, RCB:RCB1961, TKG:TKG 0406, TOKU-E:2235, Ubigene:YC-C088, Wikidata:Q54903053

ID: CVCL_1384

Hierarchy: cvcl_0397

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260905T181044+0000

Ratings and Alerts

No rating or validation information has been found for LS174T.

Warning: Discontinued: RCB; RCB1961
Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line. Warning: Discontinued: ATCC; CCL-188
Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 434 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Thorhallsdottir G, et al. (2026) Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot. Cancer immunology research, 14(6), 919.

Zheng D, et al. (2026) Oral administration of low-molecular-weight heparin ameliorates colitis by enhancing the gut mucus barrier via microbial tryptophan metabolites. British journal of pharmacology, 183(3), 560.

Young TM, et al. (2026) CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. Cancers, 18(5).

He H, et al. (2026) L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability. Oncogene, 45(12), 1071.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE?? with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. Journal of medicinal chemistry.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. Cell reports. Medicine, 102534.

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Sun X, et al. (2026) The Pivotal Role of GR-CAR Pathway in Fetal Programming of Hepatic Cytochrome P450 3A Alteration in Adulthood. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(6), e15583.

Lee CJ, et al. (2026) The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. Signal transduction and targeted therapy, 11(1), 19.

Sarkar S, et al. (2026) LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. ACS applied bio materials, 9(4), 1989.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. Oncology research, 34(2), 20.

Wang B, et al. (2026) MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. Neoplasia (New York, N.Y.), 73, 101270.

Behl A, et al. (2026) Activation of an adaptive antitumor immune response by the polymeric fluoropyrimidine CF10 involves TS/Top1 dual targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 199, 119399.

Dohnalov?? K, et al. (2026) Pregnane X receptor antagonist MI-891 reduces hepatic triglycerides in PXR-CAR-CYP3A4/3A7-humanized mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 197, 119168.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. Cell reports, 45(5), 117338.

Chen Y, et al. (2026) Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution. ChemMedChem, 21(11), e70325.

Kobayashi H, et al. (2026) A self-amplifying nerve-fibroblast circuit drives colorectal cancer progression. Cancer cell.

Ramzy GM, et al. (2025) Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells. International journal of molecular sciences, 26(3).

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Pan X, et al. (2025) Development and Preclinical Evaluation of CDH17-Specific ImmunoPET Imaging in Colorectal Cancers. Molecular pharmaceutics, 22(9), 5512.